Kelsea Carlson practices general corporate and securities law. She represents both private and public companies across a wide range of matters, including company formations, corporate governance matters, venture capital and other private financings, mergers and acquisitions and public offerings.

Download full bio 


  • Angion Biomedica – $92 Million IPO 

  • C4 Therapeutics – $210 Million IPO 

  • Sunrun to Acquire Vivint Solar for Enterprise Value of $3.2 Billion 

  • Sana Biotechnology - $676 million IPO 

  • Olema - $240 million IPO 


  • University of California, Berkeley, School of Law
    JD, 2018

  • Tufts University
    BA, International Relations
    magna cum laude, 2013

Admissions & Credentials